This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Drug-Induced Neutropenia" led by Brian Curtis from the Platelet and Neutrophil Immunology Laboratory at Versiti Blood Center of Wisconsin in Milwaukee, stands out. This session will delve into the complexities of drug-induced neutropenia, a significant and often challenging condition encountered in clinical practice. Attendees will gain a deeper understanding of the mechanisms behind drug-induced neutropenia, the latest diagnostic approaches, and strategies for management and treatment. This exploration promises to provide valuable insights into mitigating the risks associated with drug therapies and enhancing patient safety. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.
Sanquin Health Solutions’ Post
More Relevant Posts
-
In a new study, researchers at Weill Cornell Medicine, including CRI Lloyd J. Old STAR Dr. Gregory Sonnenberg, identified a previously unknown link between two key pathways that regulate the immune system in mammals. "Until now, most research on CTLA-4 focused on T cells, another type of immune cell. By uncovering that it is selectively upregulated on ILC3s by IL-23, this demonstrates that we should be thinking about these pathways more broadly to develop more selective therapeutics," describes Dr. Sonnenberg. Discover: https://bit.ly/4b7Msdp #Immunotherapy #CancerResearch #IBD #TCells
-
Sharing an exciting new development from the University of Erlangen Rheumatology and Immunology group that was recently published in the New England Journal of Medicine. A small open label trial involving 4 patients with multi-treatment refractory autoimmune diseases (Sjogren's Syndrome, Systemic Sclerosis, Rheumatoid Arthritis, and Dermatomyositis) demonstrated that Teclistamab, a BCMA/CD19 Bispecific T-cell Engager (BiTE), was safe and efficacious. This is a major clinical and scientific breakthrough as these patients had previously not responded well to Rituximab, an anti-CD20 monoclonal antibody. Together, these data suggest that BCMA-expressing plasma cells may be driving disease activity in these patients. https://lnkd.in/emXpwDej #rheumatology #autoimmunity #science #plasmacells #BiTE
-
ELISpot immunoassays are essential tools for detecting and quantifying cytokine-secreting cells at the single-cell level. Confidently detect Human IL-6, IFN-γ, and TNF-α and drive your immunology research further.
ELISpot immunoassays are essential tools for detecting and quantifying cytokine-secreting cells at the single-cell level. Confidently detect Human IL-6, IFN-γ, and TNF-α and drive your immunology research further. https://bit.ly/4cmZqoH
-
-
Professor of Translational Gastroenterology bei Charité - University Medicine Berlin
📢 Proud to share our latest publication in Gastroenterology on advancing personalized therapy for inflammatory bowel disease (IBD)! Our team conducted a prospective cohort study to investigate immune responses to vedolizumab, a monoclonal antibody treatment for ulcerative colitis and Crohn's disease. While vedolizumab shows promise in achieving remission by blocking lymphocyte homing to the gut, a portion of patients still do not respond effectively. In this study, we applied advanced multimodal profiling to analyze immune cell changes in the blood of IBD patients before and after treatment. Our findings revealed shifts in innate and adaptive immune cell populations, with a specific T-cell signature emerging as a predictor of treatment response. These insights, powered by machine learning models, may help clinicians identify patients likely to benefit from vedolizumab, moving us closer to personalized IBD care. 🌟 A huge thank you to my brilliant lab members and collaborators at Charité, BIH, DRFZ, and the University of Bonn for their hard work and dedication. We are grateful for the support from the Volkswagen Foundation, ERC, and the DFG, which made this study possible. Check out the full paper here: https://lnkd.in/ep38SvHP #IBD #Vedolizumab #PrecisionMedicine #Gastroenterology
Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7–Blocking Therapy in Inflammatory Bowel Disease
sciencedirect.com
-
We’re leveraging our deep scientific expertise to revolutionize the treatment of immuno-inflammatory diseases by building an industry-leading pipeline of oral medicines. Today on the International Day of Immunology, hear from our VP of Clinical Development, Arsalan S. Qazi MD, PhD, on how we’re pioneering paradigm-changing medicines and the future of immunology. #DayofImmunology #TPD #ReinventingMedicine
-
ELISpot immunoassays are essential tools for detecting and quantifying cytokine-secreting cells at the single-cell level. Confidently detect Human IL-6, IFN-γ, and TNF-α and drive your immunology research further. https://bit.ly/4cmZqoH
-
-
Congratulations to C-Path’s Joseph Hedrick on his co-authorship of the newly published paper in Frontiers in Immunology, TNF-α Inhibitors for Type 1 Diabetes: Exploring the Path to a Pivotal Clinical Trial. This important work examines the potential of TNF-α inhibitors to preserve β-cell function in people with type 1 diabetes, a critical factor in improving clinical outcomes. The paper outlines the pathway to pivotal trials for this promising therapy, offering hope for the development of disease-modifying treatments in T1D—a condition that currently lacks approved therapies to alter its course. Research like this pushes the boundaries of what’s possible for those with T1D, and we’re proud to see C-Path contributing to such impactful advancements. Read the full publication to learn more about the potential for TNF-α inhibitors in T1D treatment: https://lnkd.in/gsmMfk8U. #CPath #Type1Diabetes #T1DResearch #AutoimmuneDisease #ClinicalTrials #DrugDevelopment #Biotechnology #PubMed #RegenerativeMedicine #TNFAlpha
-
-
🔬 Indian Journal of Rheumatology and Clinical Immunology is inviting submissions for our upcoming research! We welcome manuscripts on a wide range of topics within rheumatology and clinical immunology, including but not limited to rare co-existences like Ankylosing Spondylitis with Systemic Lupus Erythematosus. 📚 Submit your research, case reports, and reviews to contribute to the advancement of rheumatology and clinical immunology. Submit your manuscripts here: [ https://lnkd.in/eZHPFUXb ] #research #researchpaper #casereport #medicalresearch #medical #doctors #medicalpractice #medicaldoctor #manuscripts #reviews #rheumatology #rheumatologist #rheumatoid #rheumatoidarthritis #rheumatoidarthritisawareness
-
-
🔬 Delving into autoimmune breakthroughs! We're thrilled to share the progress we´ve made in combating #type1diabetes with Ahead´s innovative technology. Our latest research, published in the Journal of Autoimmunity, offers an in-depth look into the mechanism of action of macrophages in the generation of tolerance in our immunotherapy. 📚 📖 Explore the details of the study: https://lnkd.in/gsMe6Ejd
🆕 Progress in developing specific immunotherapies for type 1 diabetes Researchers from Germans Trias i Pujol Research Institute (IGTP) and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials. 🗣️ The principal investigator of the study, Marta Vives Pi, leader of IGTP's Immunology of Diabetes Research Group, highlights "the serious public health problem posed by the more than 80 existing autoimmune diseases, which affect 1 in 10 people, and for which there is still no possibility of prevention or cure". 🗣️ David Perna-Barrull, first author of the study alongside Iván García Loza, states: "We believe that just as it acts on immune system cells in people with type 1 diabetes, it will do so in other autoimmune diseases, all characterised by a loss of tolerance to one's own tissues". Read more: https://lnkd.in/d5f4vgaA #Research #Immunotherapy #ImmunotherapyResearch #Type1Diabetes #T1D
News
germanstrias.org
-
🔬 Indian Journal of Rheumatology and Clinical Immunology is inviting submissions for our upcoming research! We welcome manuscripts on a wide range of topics within rheumatology and clinical immunology, including but not limited to rare co-existences like Ankylosing Spondylitis with Systemic Lupus Erythematosus. 📚 Submit your research, case reports, and reviews to contribute to the advancement of rheumatology and clinical immunology. Submit your manuscripts here: [ https://lnkd.in/eZHPFUXb ] #research #researchpaper #casereport #medicalresearch #medical #doctors #medicalpractice #medicaldoctor #manuscripts #reviews #rheumatology #rheumatologist #rheumatoid #rheumatoidarthritis #rheumatoidarthritisawareness
-
